诚达药业(301201) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥88,418,646.40, a decrease of 6.64% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥26,956,187.26, an increase of 37.74% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥15,226,607.83, down 24.29% from the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.2788, reflecting a 3.31% increase year-on-year[5] - The net profit for the third quarter of 2022 was CNY 91,990,029.78, an increase of 30.9% compared to CNY 70,372,208.94 in the same period last year[21] - Operating profit reached CNY 109,884,155.18, up from CNY 82,963,144.01, reflecting a growth of 32.3% year-over-year[21] - The total comprehensive income attributable to the parent company was CNY 92,047,145.90, compared to CNY 70,504,796.15 in the previous year, marking a growth of 30.5%[21] Assets and Equity - Total assets at the end of Q3 2022 reached ¥2,289,275,234.90, representing a 235.07% increase compared to the end of the previous year[5] - As of September 30, 2022, the total assets of Chengda Pharmaceutical Co., Ltd. amounted to CNY 2,289,275,234.90, a significant increase from CNY 683,227,154.78 at the beginning of the year[17] - The total equity attributable to shareholders increased to CNY 2,199,783,842.96 from CNY 529,243,641.45, indicating a significant growth in shareholder value[19] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥12,955,580.95, a significant decrease of 85.17%[9] - Cash flow from operating activities generated CNY 12,955,580.95, a significant decrease of 85.2% compared to CNY 87,375,186.65 in the previous year[22] - The company experienced a decrease in cash flow from operating activities due to increased cash payments for goods and services, totaling CNY 198,426,196.31, up from CNY 107,465,682.07[22] - The company reported a net cash outflow from investing activities of CNY -1,102,244,307.66, compared to CNY -116,301,731.56 in the same period last year[23] - The company raised CNY 1,640,224,998.21 from financing activities, a substantial increase compared to CNY 46,401,624.00 in the previous year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,385[11] - The largest shareholder, Ge Jianli, holds 27.17% of shares, totaling 26,269,600 shares[11] - Shenzhen Shengtai Investment Management Co., Ltd. holds 16.03% of shares, totaling 15,500,000 shares[11] - Huang Honglin, another major shareholder, owns 12.62% of shares, amounting to 12,205,000 shares[11] - The total number of restricted shares at the end of the period is 73,318,970[14] - The company has no new restricted shares added during the reporting period[14] - The total number of shares held by the top ten unrestricted shareholders is 1,645,000[14] - The company plans to lift restrictions on certain shares by January 2023[14] - The total number of shares held by WANG ZHE and Shenzhen Jiuheng Investment Advisory Co., Ltd. is 2,000,000 each[14] - The company has a strategic placement plan for employee participation with 796,865 shares[14] Operational Highlights - The company reported a significant increase in prepayments, which rose by 322.58% to ¥21,903,046.51 due to increased raw material payments[8] - Chengda Pharmaceutical established a new subsidiary, Shanghai Ruijiyuan Biotechnology Co., Ltd., with a total investment of CNY 20 million, enhancing its operational capabilities in biotechnology[15] - The company's inventory as of September 30, 2022, was CNY 173,794,253.43, up from CNY 104,183,626.72 at the beginning of the year, reflecting a growth of approximately 66.8%[17] - Research and development expenses for the third quarter of 2022 were CNY 14,626,261.48, compared to CNY 11,720,223.57 in the previous year, marking an increase of approximately 25.8%[20] Financial Performance Comparison - The company's total revenue for the third quarter of 2022 was CNY 305,647,514.60, representing an increase of 5.5% compared to CNY 289,859,993.58 in the same period last year[20] - The total operating costs for the third quarter of 2022 were CNY 231,232,772.85, up from CNY 211,715,175.40 year-over-year, indicating a rise of approximately 9.2%[20] - The company reported a financial income of CNY 1,024,724.41 for the third quarter of 2022, compared to CNY 229,934.80 in the same period last year, indicating a strong improvement in financial performance[20]